Latest Safety News

Invion Limited has addressed ASX queries over the timing and content of its cleansing notice, confirming encouraging early results from its Phase I/II non-melanoma skin cancer trial using Photosoft™ technology.

PYC Therapeutics has secured Safety Review Committee approval to increase dosing in its clinical trial for a novel treatment targeting Autosomal Dominant Optic Atrophy, a rare blinding genetic disease. This milestone marks a significant step forward in the development of PYC-001, a first-in-class RNA therapy.

Etherstack has landed a $1 million contract to supply digital radio network equipment to the world’s largest iron ore producer in Western Australia, reinforcing its growth in recurring revenues. The company also reports record cash receipts in the first half of 2025, signaling strong momentum.

QuickFee Limited has launched a Share Purchase Plan offering up to 5 million new shares at a 2% discount, aiming to raise $250,000 to fuel loan book growth and strengthen its balance sheet. Neu Capital Australia Pty Ltd has committed to cover any shortfall, underscoring confidence in QuickFee’s growth trajectory.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Synertec Corporation has signed a 12-month MOU with global battery leader Ritar International to integrate advanced OPzV battery technology into its Powerhouse microgrid system, aiming to slash costs and scale production rapidly.

Breakthrough Minerals has completed the acquisition of the Errolls Gold Project in Western Australia and raised $1.2 million to fund an upcoming drilling program targeting high-grade gold mineralisation.

HyTerra Limited has successfully completed the Blythe 13-20 well at its Nemaha Project, confirming promising hydrogen and helium presence and expanding its drilling program to three wells.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Cazaly Resources has secured key approvals to commence drilling at the Duke of York prospect within its Goongarrie Gold Project, aiming to validate promising historical gold intercepts and explore new mineralisation along a prolific gold corridor in Western Australia.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.